-
Je něco špatně v tomto záznamu ?
Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor
J. Tack, B. Vladimirov, I. Horny, CF. Chong, J. Eisner, R. Czerniak, Y. Takanami
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu randomizované kontrolované studie, klinické zkoušky, fáze II, časopisecké články, práce podpořená grantem
NLK
Medline Complete (EBSCOhost)
od 1998-12-01 do Před 1 rokem
Wiley Free Content
od 1997 do Před 18 měsíci
PubMed
36178335
DOI
10.1111/nmo.14468
Knihovny.cz E-zdroje
- MeSH
- dvojitá slepá metoda MeSH
- esomeprazol * terapeutické užití MeSH
- gastroezofageální reflux * farmakoterapie diagnóza MeSH
- inhibitory protonové pumpy terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- pyróza farmakoterapie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze II MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: Proton-pump inhibitors (PPIs) are cornerstone treatments for gastro-esophageal reflux disease (GERD); however, evidence suggests that most patients exhibit partial response to PPIs, suggesting the need for novel therapies that can provide an improved and sustained increase in gastric pH. AIMS: This study aimed to determine the effect of vonoprazan, a novel, orally active small-molecule potassium-competitive acid blocker, versus esomeprazole, a PPI, in preventing heartburn symptoms over a 4-week treatment period in patients with GERD and a partial response to esomeprazole treatment. METHODS: This randomized, double-blind, proof-of-concept, phase 2 clinical trial was conducted between 2016 and 2018 at 39 sites across Europe and designed to evaluate the efficacy and safety of vonoprazan 20 mg once daily (q.d.) and 40 mg q.d. versus esomeprazole 40 mg q.d. after 1:1:1 randomization of symptomatic patients with GERD and a partial response to a healing dose of esomeprazole. RESULTS: Overall, 256 eligible patients (female, 59.4%; mean age, 52.6 years) received vonoprazan 20 mg (n = 85), vonoprazan 40 mg (n = 85), or esomeprazole 40 mg (n = 86); mean (SD) percentages of heartburn-free 24-h periods during double-blind treatment were 36.7% (33.4%), 36.5% (35.6%), and 38.4% (34.8%), respectively, with no intergroup statistical significance. Vonoprazan exposure increased proportionally from the 20-mg to 40-mg dose (mean Cmax : 23.3 ng/ml to 47.1 ng/ml, respectively). Most treatment-emergent adverse events were mild, with no deaths reported. CONCLUSIONS: No statistically significant difference in efficacy and safety was observed among treatment groups, and vonoprazan was well tolerated. The trial is registered with the National Board of Health (EudraCT: 2015-001154-14) database.
Currently Hoffmann La Roche Formerly Takeda Development Center Asia Basel Switzerland
Department of Gastroenterology and Internal medicine Strakonice Hospital Czech Republic
Department of Gastroenterology University Hospitals Leuven Leuven Belgium
Takeda Pharmaceuticals International Co Cambridge Massachusetts USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032072
- 003
- CZ-PrNML
- 005
- 20230131150722.0
- 007
- ta
- 008
- 230120s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/nmo.14468 $2 doi
- 035 __
- $a (PubMed)36178335
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Tack, Jan $u Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium
- 245 10
- $a Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor / $c J. Tack, B. Vladimirov, I. Horny, CF. Chong, J. Eisner, R. Czerniak, Y. Takanami
- 520 9_
- $a BACKGROUND: Proton-pump inhibitors (PPIs) are cornerstone treatments for gastro-esophageal reflux disease (GERD); however, evidence suggests that most patients exhibit partial response to PPIs, suggesting the need for novel therapies that can provide an improved and sustained increase in gastric pH. AIMS: This study aimed to determine the effect of vonoprazan, a novel, orally active small-molecule potassium-competitive acid blocker, versus esomeprazole, a PPI, in preventing heartburn symptoms over a 4-week treatment period in patients with GERD and a partial response to esomeprazole treatment. METHODS: This randomized, double-blind, proof-of-concept, phase 2 clinical trial was conducted between 2016 and 2018 at 39 sites across Europe and designed to evaluate the efficacy and safety of vonoprazan 20 mg once daily (q.d.) and 40 mg q.d. versus esomeprazole 40 mg q.d. after 1:1:1 randomization of symptomatic patients with GERD and a partial response to a healing dose of esomeprazole. RESULTS: Overall, 256 eligible patients (female, 59.4%; mean age, 52.6 years) received vonoprazan 20 mg (n = 85), vonoprazan 40 mg (n = 85), or esomeprazole 40 mg (n = 86); mean (SD) percentages of heartburn-free 24-h periods during double-blind treatment were 36.7% (33.4%), 36.5% (35.6%), and 38.4% (34.8%), respectively, with no intergroup statistical significance. Vonoprazan exposure increased proportionally from the 20-mg to 40-mg dose (mean Cmax : 23.3 ng/ml to 47.1 ng/ml, respectively). Most treatment-emergent adverse events were mild, with no deaths reported. CONCLUSIONS: No statistically significant difference in efficacy and safety was observed among treatment groups, and vonoprazan was well tolerated. The trial is registered with the National Board of Health (EudraCT: 2015-001154-14) database.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a esomeprazol $x terapeutické užití $7 D064098
- 650 _2
- $a inhibitory protonové pumpy $x terapeutické užití $7 D054328
- 650 _2
- $a výsledek terapie $7 D016896
- 650 12
- $a gastroezofageální reflux $x farmakoterapie $x diagnóza $7 D005764
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a pyróza $x farmakoterapie $7 D006356
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a klinické zkoušky, fáze II $7 D017427
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vladimirov, Borislav $u Department of Gastroenterology, University Hospital "Queen Giovanna- ISUL", Medical University of Sofia, Sofia, Bulgaria
- 700 1_
- $a Horny, Ivo $u Department of Gastroenterology and Internal medicine, Strakonice Hospital, Czech Republic
- 700 1_
- $a Chong, Chui Fung $u Currently Hoffmann-La Roche, Formerly Takeda Development Center Asia, Basel, Switzerland
- 700 1_
- $a Eisner, Jessica $u Formerly Takeda Pharmaceuticals International Co., Takeda Pharmaceuticals International Co., Cambridge, USA
- 700 1_
- $a Czerniak, Richard $u Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA
- 700 1_
- $a Takanami, Yohei $u Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA
- 773 0_
- $w MED00005047 $t Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society $x 1365-2982 $g Roč. 35, č. 1 (2023), s. e14468
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36178335 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131150718 $b ABA008
- 999 __
- $a ok $b bmc $g 1891068 $s 1183407
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 35 $c 1 $d e14468 $e 20220930 $i 1365-2982 $m Neurogastroenterology and motility $n Neurogastroenterol Motil $x MED00005047
- LZP __
- $a Pubmed-20230120
